ChondroNest SA develops a patented composition of modified biopolymers from the extracellular matrix designed to reconstruct cartilage. The technology is a surgeon-placeable, shapeable paste that solidifies under biocompatible conditions to reconstruct the ECM scaffold in vivo; the company is pursuing preclinical studies toward applications in hyaline cartilage repair.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentMedical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Patented composition of modified biopolymers for in-vivo reconstruction of cartilage and the extracellular matrix; developed as a mouldable paste for surgical use.
Development of hyaline cartilage applications
Development of the application of the protected technology for the reconstruction of hyaline cartilage; preclinical tests on animal models for osteochondritis and osteoarthritis are planned.
Licensing medical technology to MedTech companies
After the first preclinical in-man studies, the product is to be licensed to large MedTech companies for sales and marketing; production of the ChondroNest™ pastes remains with the company.
Knowledge
No knowledge articles yet
Once ChondroNest SA has claimed this profile, we'll publish editorial articles and case studies here together.